Production (Stage)
Ikena Oncology, Inc.
IKNA
$1.43
$0.064.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -98.79% | -18.89% | |||
| Gross Profit | 98.79% | 18.89% | |||
| SG&A Expenses | -21.76% | -25.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.81% | -23.13% | |||
| Operating Income | 9.81% | 23.13% | |||
| Income Before Tax | 67.97% | 5.29% | |||
| Income Tax Expenses | -46.43% | -47.17% | |||
| Earnings from Continuing Operations | 67.90% | 5.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 67.90% | 5.53% | |||
| EBIT | 9.81% | 23.13% | |||
| EBITDA | 9.90% | 23.28% | |||
| EPS Basic | 67.92% | 5.55% | |||
| Normalized Basic EPS | 65.91% | 18.04% | |||
| EPS Diluted | 67.92% | 5.55% | |||
| Normalized Diluted EPS | 65.91% | 18.04% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||